revumenib citrate
View Patient InformationThe monocitrate monohydrate form of revumenib, an orally bioavailable protein-protein interaction (PPI) inhibitor of menin with both wild-type and fusion proteins of lysine methyltransferase 2A (mixed lineage leukemia MLL; myeloid/lymphoid leukemia; KMT2A), with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and KMT2A and the formation of the menin-KMT2A complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of KMT2A-rearranged leukemic cells. The menin-KMT2A complex induces the transcription of various genes involved in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.
| Synonym: | benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-N-(1-methylethyl)-, 2-hydroxy-1,2,3-propanetricarboxylate, hydrate (1:1:1) menin-MLL interaction inhibitor SNDX-5613 revumenib monocitrate monohydrate |
|---|---|
| US brand name: | Revuforj |
| Chemical structure: | benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-N-(1-methylethyl)- |